The essentials
FDA launches safety review of mifepristone, approved since 2000 and used in majority of U.S. abortions.
The FDA is conducting a safety review of mifepristone, the medication used in medical abortions and miscarriage management, under the Trump administration. This review marks a shift in federal drug evaluation priorities for a medication with established FDA approval dating to 2000 and a two-decade history of regulatory oversight.
Mifepristone accounts for over 60 percent of U.S. abortions, making it central to American reproductive healthcare. The medication's clinical prevalence reflects its integration into standard medical practice across the country.
The safety review occurs amid broader legal and regulatory contestation surrounding mifepristone's distribution methods. Supreme Court precedent from 2024 affirmed that existing FDA approval and access mechanisms cannot be unilaterally dismantled, constraining lower courts' authority to reverse the agency's determinations. However, the new federal review process introduces additional scrutiny into the medication's regulatory status, creating uncertainty about its future availability despite its established safety profile and widespread clinical use.
Other ways to read this story.
Alternative framings generated by SigNews. These are not independent sources or attributed quotations.
FDA Review Examines Medication With Two Decades of Approval History
Mifepristone's regulatory foundation extends over two decades of federal oversight, beginning with FDA approval in 2000 that established the drug as safe for medical abortion. This established baseline creates the regulatory context for the current safety review. The medication has been available via telemedicine prescription since 2021, following FDA regulatory changes that expanded access. The review process examines a medication already integrated into standard pharmaceutical practice and clinical protocols across the country.
Safety Review Occurs Within Constraints of Supreme Court Precedent
The FDA's safety review unfolds within a defined legal landscape. The Supreme Court unanimously rejected a mifepristone challenge in 2024, affirming that existing FDA approval and access mechanisms cannot be unilaterally dismantled. This precedent establishes binding constraints on how regulatory reviews can alter the medication's approved status. The current safety review operates within these judicial boundaries that protect the FDA's authority to maintain approved drugs' existing regulatory frameworks.